Wall Street analysts expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to post earnings of ($1.45) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($1.42) and the lowest estimate coming in at ($1.49). Atara Biotherapeutics reported earnings of ($1.15) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 26.1%. The business is expected to issue its next quarterly earnings results on Wednesday, August 7th.
On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($5.54) per share for the current year, with EPS estimates ranging from ($5.93) to ($5.21). For the next fiscal year, analysts anticipate that the business will report earnings of ($5.31) per share, with EPS estimates ranging from ($6.12) to ($4.63). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.48) by $0.04.
NASDAQ:ATRA opened at $20.00 on Friday. Atara Biotherapeutics has a 1 year low of $19.95 and a 1 year high of $43.95. The stock has a fifty day simple moving average of $23.43. The company has a quick ratio of 9.96, a current ratio of 9.96 and a debt-to-equity ratio of 0.05.
In other news, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $39.96, for a total value of $59,940.00. Following the completion of the sale, the insider now owns 63,646 shares in the company, valued at $2,543,294.16. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Isaac E. Ciechanover sold 3,900 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $37.04, for a total value of $144,456.00. Following the completion of the sale, the chief executive officer now owns 332,243 shares of the company’s stock, valued at approximately $12,306,280.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,150 shares of company stock valued at $1,147,091. Insiders own 7.00% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. FMR LLC increased its position in Atara Biotherapeutics by 21.7% in the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock worth $255,114,000 after purchasing an additional 1,143,787 shares during the last quarter. Redmile Group LLC increased its position in Atara Biotherapeutics by 1.6% in the 1st quarter. Redmile Group LLC now owns 4,485,417 shares of the biotechnology company’s stock worth $178,295,000 after purchasing an additional 70,800 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Atara Biotherapeutics during the 1st quarter valued at about $1,961,000. Marshall Wace LLP acquired a new position in shares of Atara Biotherapeutics during the 1st quarter valued at about $284,000. Finally, Neuberger Berman Group LLC increased its holdings in shares of Atara Biotherapeutics by 1.3% during the 1st quarter. Neuberger Berman Group LLC now owns 1,306,651 shares of the biotechnology company’s stock valued at $51,939,000 after acquiring an additional 16,703 shares during the last quarter.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Article: What is the downside to momentum investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.